Add-onWednesday, September 9, 2026
Iron Path-backed VION Biosciences completes acquisition of Prolytix
Prolytix provides regulated bioanalytical and CMC services, research reagents and custom sample collection products to biopharma and diagnostics customers.
Prolytix offers regulated bioanalytical and CMC services, research reagents, and custom sample collection products to biopharma and diagnostics customers.
Deal facts
- Target
- Prolytix
- Business
- Provider of regulated bioanalytical and CMC services, research reagents, and custom sample collection products for biopharma and diagnostics customers
- Acquirer
- VION Biosciences
- Backed by
- Iron Path Capital
- Deal type
- Add-on
- Status
- Completed
- Announced
- Wednesday, September 9, 2026
Sources
- PEI Private EquitySep 9, 2026
Written by Buyout Desk from the sources above. Spotted an error? Email corrections@buyoutdesk.com.